Axe Compute (AGPU) Registration Filing summary

Company overview and business model

• Applies artificial intelligence and a proprietary biobank of over 150,000 tumor samples to optimize oncology drug discovery and development, offering AI-driven solutions from early discovery to clinical trials.

• Operates a digital asset treasury strategy focused on Aethir (ATH) tokens, functioning as an operator in the Aethir ecosystem to support AI infrastructure.

• Provides contract research, proprietary 3D cell culture models, and digital asset management services.

Financial performance and metrics

• As of October 21, 2025, held approximately 5.45 billion ATH tokens valued at $174.4 million.

• Recent private placements raised $50.77 million in cash and $173.3 million in ATH tokens (discounted value) in September 2025.

• Audit reports for 2023 and 2024 include going concern warnings due to recurring losses and accumulated deficit.

Use of proceeds and capital allocation

• Proceeds from warrant exercises will be used to acquire additional ATH, fund the Treasury Strategy, and for general corporate and working capital purposes.

• In-kind ATH contributions from recent offerings are allocated to the Treasury Strategy.